Podcast #59 · 12 May 2026
Evolving Treatment Paradigms in Hepatocellular Carcinoma: What's on the Horizon?
- Medical Oncology
- Liver Transplant
- Neoadjuvant Immunotherapy
- Gastroenterology
- Liver Cancer
- Y90 Radioembolization
- Immunotherapy
- Hepatocellular Carcinoma (HCC)
- CAR T-Cell Therapy
- Hepatology
- 2026 HCC Creator Weekend™
With new systemic and liver-directed approaches under investigation, which targets and treatment strategies are most likely to shape HCC care? In this final episode of the BackTable 2026 HCC Creator Weekend™, Drs. Lingling Du, A. Craig Lockhart, and Jon Mizrahi focus on the future of hepatocellular carcinoma beyond established PD-1/CTLA-4 regimens.
Timestamps
More about this episode
The clinicians discuss promising results from emerging immune checkpoint targets like anti-TIGIT and note ongoing interest in other targets like TIM-3. They emphasize combining systemic immunotherapy with liver-directed therapies like Y90 across heterogeneous patient groups and discuss potential neoadjuvant approaches for resectable cases, despite limited benefit seen in adjuvant studies. Additionally, they outline early-phase cellular and targeted strategies, such as GPC3-directed bispecifics and CAR T-cell therapies, noting tolerance challenges tied to liver function and the risks of using immunotherapy after liver transplant.